What Is Immix Biopharma, Inc. (IMMX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Immix Biopharma, Inc.'s intrinsic value is estimated at $3.21, suggesting the stock is overvalued at its current price of $10.53. With 8 out of 8 models flagging downside (-69.5% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $8.60 (-18.3%), while Dynamic NAV — the most conservative — estimates $1.19 (-88.7%). This +70.3% gap reflects genuine analytical uncertainty about Immix Biopharma, Inc.'s intrinsic worth.
What Do the Models Say About IMMX?
8 of 13 models are currently active for IMMX. All 8 active models suggest the stock trades above fair value. The Bayesian DCF estimates IMMX's intrinsic value at $2.92, implying -72.2% downside from the current price. See which stocks rank higher →
How Does IMMX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, IMMX ranks #141 by Quality of Company score. CirclFi's QOC score of 5.8/10 evaluates 32 fundamental signals. A score of 5.8 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, Immix Biopharma, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating IMMX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is IMMX a Value Trap?
CirclFi's Value Trap algorithm assigns IMMX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for Immix Biopharma, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Immix Biopharma, Inc.'s fundamental quality profile registers 5.8/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +70.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every IMMX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across IMMX's 8 active models, average confidence is 23%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad